SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-061643
Filing Date
2020-03-04
Accepted
2020-03-04 16:22:17
Documents
17
Period of Report
2020-03-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d853015d8k.htm   iXBRL 8-K 34470
2 EX-1.1 d853015dex11.htm EX-1.1 199892
3 EX-5.1 d853015dex51.htm EX-5.1 11215
4 EX-99.1 d853015dex991.htm EX-99.1 14346
8 GRAPHIC g853015g0304104913117.jpg GRAPHIC 3606
9 GRAPHIC g853015g68o59.jpg GRAPHIC 1946
  Complete submission text file 0001193125-20-061643.txt   455775

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA kpti-20200303.xsd EX-101.SCH 3074
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE kpti-20200303_lab.xml EX-101.LAB 18137
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kpti-20200303_pre.xml EX-101.PRE 11410
10 EXTRACTED XBRL INSTANCE DOCUMENT d853015d8k_htm.xml XML 3348
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

IRS No.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36167 | Film No.: 20687478
SIC: 2834 Pharmaceutical Preparations